Lipocine Inc
LPCN4.250USD
+0.050+1.19%
收盤 12/19, 16:00（美東）報價延遲15分鐘
23.04M總市值
虧損本益比TTM
關於 Lipocine Inc 公司
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Lipocine Inc簡介
公司代碼LPCN
公司名稱Lipocine Inc
上市日期Mar 21, 2014
CEOPatel (Mahesh V)
員工數量16
證券類型Ordinary Share
年結日Mar 21
公司地址675 S Arapeen Dr Ste 202
城市SALT LAKE CITY
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編84108-1295
電話18019947383
網址https://www.lipocine.com/
公司代碼LPCN
上市日期Mar 21, 2014
CEOPatel (Mahesh V)
Lipocine Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.05K
+1.52%
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
40.80K
--
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.41K
+11.54%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.07K
+44.84%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
Dr. Jill M. Jene, Ph.D.
Dr. Jill M. Jene, Ph.D.
Independent Director
Independent Director
--
--
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.05K
+1.52%
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
40.80K
--
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.41K
+11.54%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.07K
+44.84%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
4.00%
Patel (Mahesh V)
1.96%
BlackRock Institutional Trust Company, N.A.
1.61%
Geode Capital Management, L.L.C.
1.10%
Susquehanna International Group, LLP
0.84%
其他
90.49%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
4.00%
Patel (Mahesh V)
1.96%
BlackRock Institutional Trust Company, N.A.
1.61%
Geode Capital Management, L.L.C.
1.10%
Susquehanna International Group, LLP
0.84%
其他
90.49%
股東類型
持股股東
佔比
Investment Advisor
6.76%
Individual Investor
2.84%
Investment Advisor/Hedge Fund
1.89%
Hedge Fund
0.93%
其他
87.58%
機構持股
更新時間: 10月5日 週日
更新時間: 10月5日 週日
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
32
528.39K
9.52%
-40.19K
2025Q2
44
680.47K
12.56%
-41.55K
2025Q1
65
678.55K
12.68%
-110.89K
2024Q4
72
645.33K
12.07%
-219.30K
2024Q3
75
703.77K
13.16%
-136.61K
2024Q2
79
690.86K
12.92%
-132.01K
2024Q1
82
639.82K
12.02%
-214.82K
2023Q4
86
649.80K
12.29%
-222.39K
2023Q3
91
667.07K
12.61%
-176.35K
2023Q2
93
641.50K
12.32%
-239.33K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
224.88K
4.15%
-1.40K
-0.62%
Jun 30, 2025
Patel (Mahesh V)
109.05K
2.01%
+1.63K
+1.52%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
89.27K
1.65%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
61.08K
1.13%
+2.24K
+3.81%
Jun 30, 2025
Susquehanna International Group, LLP
46.02K
0.85%
+7.04K
+18.06%
Jun 30, 2025
Higuchi (John W)
40.80K
0.75%
--
--
Mar 31, 2025
Renaissance Technologies LLC
34.80K
0.64%
-2.71K
-7.23%
Jun 30, 2025
State Street Investment Management (US)
18.63K
0.34%
--
--
Jun 30, 2025
Northern Trust Investments, Inc.
13.16K
0.24%
--
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%
Dimensional US Core Equity 1 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
公告日期
類型
比率
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
常見問題
Lipocine Inc的前五大股東是誰？
Lipocine Inc的前五大股東如下：
The Vanguard Group, Inc.持有股份：224.88K佔總股份比例：4.15%。
Patel (Mahesh V)持有股份：109.05K佔總股份比例：2.01%。
BlackRock Institutional Trust Company, N.A.持有股份：89.27K佔總股份比例：1.65%。
Geode Capital Management, L.L.C.持有股份：61.08K佔總股份比例：1.13%。
Susquehanna International Group, LLP持有股份：46.02K佔總股份比例：0.85%。
The Vanguard Group, Inc.持有股份：224.88K佔總股份比例：4.15%。
Patel (Mahesh V)持有股份：109.05K佔總股份比例：2.01%。
BlackRock Institutional Trust Company, N.A.持有股份：89.27K佔總股份比例：1.65%。
Geode Capital Management, L.L.C.持有股份：61.08K佔總股份比例：1.13%。
Susquehanna International Group, LLP持有股份：46.02K佔總股份比例：0.85%。
Lipocine Inc的前三大股東類型是什麼？
Lipocine Inc 的前三大股東類型分別是：
The Vanguard Group, Inc.
Patel (Mahesh V)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Patel (Mahesh V)
BlackRock Institutional Trust Company, N.A.
有多少機構持有Lipocine Inc(LPCN)的股份？
截至2025Q3，共有32家機構持有Lipocine Inc的股份，合計持有的股份價值約為528.39K，占公司總股份的9.52% 。與2025Q2相比，機構持股有所增加，增幅為-3.04%。
哪個業務部門對Lipocine Inc的收入貢獻最大？
在--，--業務部門對Lipocine Inc的收入貢獻最大，創收--，占總收入的--% 。
